Dyadic International, Inc.

DYAI ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item Jun 2024 Mar 2024 Dec 2023 Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Operating Activities
Net Income $-2.0M $-2.0M $-2.1M $-1.6M $-2.2M $-956.4K $-2.1M $-1.8M
Depreciation & Amortization — — — — — — — —
Depreciation — — — — — — — —
Amortization — — — — — — — —
Stock-Based Compensation $297.6K $306.5K $297.9K $281.3K $334.3K $330.6K $480.7K $499.9K
Net Cash from Operating Activities $-2.0M $-1.1M $-923.4K $-2.0M $-1.7M $-2.2M $-1.7M $-1.8M
Investing Activities
Capital Expenditures — — — — — — — —
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities $-2.5M $-654.9K $34.2K $3.5M $1.1M $2.8M $617.9K $-1.3M
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $0 $5.8M $0 $0 $0 $0 $141.5K $359.7K
Net Change in Cash $-4.4M $4.1M $-888.1K $1.6M $-532.5K $579.8K $-944.8K $-2.7M
Free Cash Flow — — — — — — — —
← Newer Page 2 of 5 Older →